Literature DB >> 19117726

Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis.

Adriana Rojas-Villarraga1, Francisco J Diaz, Enrique Calvo-Páramo, Juan C Salazar, Antonio Iglesias-Gamarra, Ruben D Mantilla, Juan-Manuel Anaya.   

Abstract

Rheumatoid arthritis (RA) progresses more rapidly in some patients than in others and diverse factors influence radiographic progression in a specific population. Thus, we searched for variables that are associated with an early appearance of substantial joint damage in patients with RA by using radiographic assessments. A cohort of 157 consecutively enrolled Colombian RA patients was followed for an average of 3.2+/-3.1 years. Information on patient demographics and cumulative clinical and laboratory manifestations over the course of the disease was registered, including family history of RA in first-degree relatives, extra-articular manifestations, rheumatoid factor, anti-CCP3 antibodies, TNF single nucleotide polymorphism at -308 position, and HLA-DRB1 status. Radiographs were scored according to the Sharp-van der Heijde method. Survival analyses of the time at appearance of substantial joint damage were performed by using Weibull models. A review of literature about the influence of familial RA on the progression of disease was done. Our results show that family history of RA is consistently associated with joint damage (i.e. erosive and joint narrowing disease). This effect was not found in all the populations reviewed. In addition, we confirm the effect of HLA-DRB1 shared epitope and anti-CCP seropositivity on erosive disease. Family history of RA is a key risk factor for joint damage and depends on the investigated population because variations in both additive and non-additive genetic factors and the environmental variance are specific to the population. Our results emphasize the usefulness of assessing familial disease, testing anti-CCP antibodies and genotyping HLA-DRB1 gene in patients with RA because these factors may be used to predict clinical outcomes and guide therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19117726     DOI: 10.1016/j.jaut.2008.11.004

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

Review 1.  Systemic sclerosis: a world wide global analysis.

Authors:  Paola Coral-Alvarado; Aryce L Pardo; Natalia Castaño-Rodriguez; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2009-03-11       Impact factor: 2.980

Review 2.  Cutting-edge issues in primary biliary cirrhosis.

Authors:  Marco Folci; Francesca Meda; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 3.  Family history of rheumatoid arthritis: an old concept with new developments.

Authors:  Thomas Frisell; Saedis Saevarsdottir; Johan Askling
Journal:  Nat Rev Rheumatol       Date:  2016-04-21       Impact factor: 20.543

4.  Immune-mediated bile duct injury: The case of primary biliary cirrhosis.

Authors:  Carlo Selmi; Andrea Affronti; Laura Ferrari; Pietro Invernizzi
Journal:  World J Gastrointest Pathophysiol       Date:  2010-10-15

5.  Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis.

Authors:  J D Goules; A V Goules; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

6.  Contributions of familial rheumatoid arthritis or lupus and environmental factors to risk of rheumatoid arthritis in women: a prospective cohort study.

Authors:  Jeffrey A Sparks; Chia-Yen Chen; Linda T Hiraki; Susan Malspeis; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-10       Impact factor: 4.794

7.  Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study.

Authors:  M A Quintana-Duque; F Rondon-Herrera; R D Mantilla; E Calvo-Paramo; J J Yunis; A Varela-Nariño; J F Restrepo; A Iglesias-Gamarra
Journal:  Clin Rheumatol       Date:  2016-04-04       Impact factor: 2.980

8.  Atypical phenotype and response of B cells in patients with seropositive rheumatoid arthritis.

Authors:  H Rincón-Arévalo; M Rojas; A Vanegas-García; C Muñoz-Vahos; J Orejuela-Erazo; G Vásquez; D Castaño
Journal:  Clin Exp Immunol       Date:  2021-03-02       Impact factor: 4.330

9.  Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis.

Authors:  Erik J M Toonen; Pilar Barrera; Jaap Fransen; Arjan P M de Brouwer; Agnes M Eijsbouts; Pierre Miossec; Hubert Marotte; Hans Scheffer; Piet L C M van Riel; Barbara Franke; Marieke J H Coenen
Journal:  Arthritis Res Ther       Date:  2012-12-07       Impact factor: 5.156

10.  PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study.

Authors:  Taku Suzuki; Katsunori Ikari; Koichiro Yano; Eisuke Inoue; Yoshiaki Toyama; Atsuo Taniguchi; Hisashi Yamanaka; Shigeki Momohara
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.